HealthCare Global Enterprises Ltd (HCG), India’s premier cancer care provider, has announced a strategic collaboration with Trucan Diagnostics Pvt Ltd to revolutionize cancer diagnostics. The partnership will focus on validating a range of cutting-edge, biomarker-driven diagnostic tests designed to enhance the detection of primary, recurrent, and metastatic cancers. These innovative tests, which utilize next-generation sequencing technologies, aim to predict treatment responses and monitor the effectiveness of chemotherapy and targeted therapies in real-time.
The collaboration will involve comprehensive validation studies, aiming to integrate these advanced diagnostic solutions into routine clinical practice, improving precision oncology across India. By personalizing treatment plans, these tests are expected to reduce ineffective therapies, minimizing costs and improving patient outcomes.
Dr. B.S. Ajaikumar, Executive Chairman of HCG, highlighted, “This collaboration marks a significant leap in precision oncology, enabling us to offer highly personalized treatment strategies to cancer patients.” Dr. Raman Govindarajan, CEO of Trucan Diagnostics, added, “We are excited to validate our diagnostic solutions in real-world settings, contributing to optimized care.” In Kolkata, this collaboration holds immense promise, as the city is witnessing a surge in cancer cases. With increasing access to advanced diagnostics, oncologists are optimistic that these new tools will provide more precise treatment options, enhancing outcomes for patients in both urban and rural areas of West Bengal.
